Page 232 - EJMO-9-3

Eurasian Journal of
Medicine and Oncology FN3K–Nrf2 axis inhibition in breast cancer

doi: 10.1021/ci800412z Fundamental algorithms for scientific computing in python.
Nat Methods. 2020;17(3):261-272.
38. Daina A, Michielin O, Zoete V. SwissADME: A free web
tool to evaluate pharmacokinetics, drug-likeness and doi: 10.1038/s41592-019-0686-2
medicinal chemistry friendliness of small molecules. Sci
Rep. 2017;7:42717. 51. Ahad NA, Syed Yahaya SS. Sensitivity analysis of Welch’s
t-test. AIP Conf Proc. 2014;1605:888-893.
doi: 10.1038/srep42717
doi: 10.1063/1.4887707
39. Li W, Zhou J, Xu Y. Study of the in vitro cytotoxicity testing
of medical devices. Biomed Rep. 2015;3(5):617-620. 52. Lee S, Lee DK. What is the proper way to apply the multiple
comparison test. Korean J Anesthesiol. 2018;71(5):353-360.
doi: 10.3892/br.2015.481
doi: 10.4097/kja.d.18.00242
40. International Organization for Standardization. ISO 10993-
5:2009. Biological Evaluation of Medical Devices-Part 5: Tests 53. Kasi A. Oxaliplatin. In: StatPearls. Treasure Island, FL:
rd
for In Vitro Cytotoxicity. 3 ed. Geneva: ISO; 2009. StatPearls Publishing; 2025. Available from: https://www.
ncbi.nlm.nih.gov/books/nbk557690 [Last accessed on
41. Senthilraja P, Kathiresan K. In vitro cytotoxicity MTT assay 2023 May 16].
in vero, HepG2 and MCF-7 cell lines study of marine yeast.
J Appl Pharm Sci. 2015;5(3):80-84. 54. Fernandez-Teruel C, Cullberg M, González-García I,
Schiavon G, Zhou D. An exposure-safety analysis to support
doi: 10.7324/JAPS.2015.50313 the dosage of the novel AKT inhibitor capivasertib. Cancer
42. Freshney RI. Culture of Animal Cells: A Manual of Basic Chemother Pharmacol. 2025;95:48.
Technique and Specialized Applications. 6 ed. Hoboken, NJ: doi: 10.1007/s00280-025-04775-8
th
Wiley-Blackwell; 2010.
55. Ahmed A, Clarke JO. Proton Pump Inhibitors (PPI). In:
43. Chomczynski P, Sacchi N. Single-step method of RNA StatPearls. Treasure Island, FL: StatPearls Publishing; 2025.
isolation by acid guanidinium thiocyanate-phenol- Available from: https://www.ncbi.nlm.nih.gov/books/
chloroform extraction. Anal Biochem. 1987;162(1):156-159. nbk557385 [Last accessed on 2023 May 01].
doi: 10.1016/0003-2697(87)90021-2 56. Lau A, Villeneuve NF, Sun Z, Wong PK, Zhang DD. Dual
44. Rio DC, Ares M Jr., Hannon GJ, Nilsen TW. Determining roles of Nrf2 in cancer. Pharmacol Res. 2008;58(5-6):262-
the yield and quality of purified RNA. Cold Spring Harb 270.
Protoc. 2010;2010(6).
doi: 10.1016/j.phrs.2008.09.003
doi: 10.1101/pdb.top82
57. Kumar H, Kumar RM, Bhattacharjee D, Somanna P, Jain V.
45. Taylor SC, Laperriere G, Germain H. Droplet digital PCR Role of Nrf2 signaling cascade in breast cancer: Strategies
versus qPCR for gene expression analysis with low abundant and treatment. Front Pharmacol. 2022;13:720076.
targets: From variable nonsense to publication quality data.
Sci Rep. 2017;7(1):2409. doi: 10.3389/fphar.2022.720076
58. Bogliolo S, Cassani C, Gardella B, et al. Oxaliplatin for the
doi: 10.1038/s41598-017-02217-x
treatment of ovarian cancer. Expert Opin Investig Drugs.
46. Livak KJ, Schmittgen TD. Analysis of relative gene 2015;24(9):1275-1286.
expression data using real-time quantitative PCR and the 2−
ΔΔCt method. Methods. 2001;25(4):402-408. doi: 10.1517/13543784.2015.1062874
doi: 10.1006/meth.2001.1262 59. Innominato PF, Karaboué A, Focan C, et al. Efficacy
and safety of chronomodulated irinotecan, oxaliplatin,
47. Pfaffl MW. A new mathematical model for relative 5-fluorouracil and leucovorin combination as first- or
quantification in real-time RT-PCR. Nucleic Acids Res. second-line treatment against metastatic colorectal cancer:
2001;29(9):e45. Results from the international EORTC 05011 trial. Int J
doi: 10.1093/nar/29.9.e45 Cancer. 2021;148(10):2512-2521.
48. Mahmood T, Yang PC. Western blot: Technique, theory, and doi: 10.1002/ijc.33422
trouble shooting. N Am J Med Sci. 2012;4(9):429-434. 60. Rugo HS, Oliveira M, Howell SJ, et al. Capivasertib
doi: 10.4103/1947-2714.100998 and fulvestrant for patients with hormone receptor-
positive advanced breast cancer: Characterization, time
49. Taylor SC, Posch A. The design of a quantitative western blot course, and management of frequent adverse events
experiment. Biomed Res Int. 2014;2014:361590. from the phase III CAPItello-291 study. ESMO Open.
doi: 10.1155/2014/361590 2024;9(9):103697.
50. Virtanen P, Gommers R, Oliphant TE, et al. SciPy 1.0: doi: 10.1016/j.esmoop.2024.103697

Volume 9 Issue 3 (2025) 224 doi: 10.36922/EJMO025150114